Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LIFE-001
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LifeMine Doses First Human in Phase 1 Trial of LIFE-001 Immunosuppressive
Details : LIFE-001 is a precision-engineered, controlled-release, organ-sparing, immunophilin-independent CNi being developed for multiple immune-mediated disease indications and organ transplant rejection.
Product Name : LIFE-001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2025
Lead Product(s) : LIFE-001
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Fidelity Management & Research Company
Deal Size : $175.0 million
Deal Type : Series C Financing
LifeMine Therapeutics Announces $175 Million Series C Financing
Details : Proceeds from the financing will be used to advance LifeMine’s proprietary, evolutionarily-derived genomic drug discovery platform, Avatar-Rx.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 23, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Fidelity Management & Research Company
Deal Size : $175.0 million
Deal Type : Series C Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
LifeMine Therapeutics and GSK Enter Drug Discovery and Development Alliance
Details : The collaboration will provide GSK with access to LifeMine’s genomically enabled drug discovery platform to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease areas.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $70.0 million
March 23, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
LifeMine Therapeutics Announces $50 Million Series B Financing
Details : Proceeds will enable advancement and acceleration of the Company’s transformative drug discovery programs derived from digital search of the fungal biosphere to discover and develop highly impactful precision medicines.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 01, 2021